Intravenous Infusions is trading 9.1% up at GHS 0.72, extending a sharp rally driven by short-term momentum and speculative interest rather than specific corporate events.
- The stock has maintained a significant upward trajectory since July 17, 2026, despite a lack of new company announcements or fundamental news.
- Market activity appears to be fueled by a supportive healthcare sector backdrop and increased speculative trading volume.
- The current move is characterized as momentum-driven, with no visible fundamental catalysts to justify the price surge.